Novo Nordisk A/S (NVO)
Pre-market:
| Previous close | 122.71 |
| Open | 122.59 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 1000 |
| Day's range | 122.57 - 126.25 |
| 52-week range | 75.56 - 138.28 |
| Volume | |
| Avg. volume | 5,017,583 |
| Market cap | 558.851B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 47.09 |
| EPS (TTM) | 2.66 |
| Earnings date | N/A |
| Forward dividend & yield | 1.37 (1.10%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 144.44 |
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i
- Yahoo Finance Video
Weight loss drugs and the many use cases in medical treatments
Novo Nordisk's (NVO) Ozempic and Wegouvy and Eli Lilly's (LLY) Zepbound are the leading names in the latest GLP-1 weight loss drug cycle, a trend that has seen a variety of use cases sprout up since these brand names' inceptions late last year. Yahoo Finance Health Reporter Anjalee Khemlani explains the new use cases being found for this class of drugs, including infertility treatments and even benefits for Alzheimer's patients. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Luke Carberry Mogan.
Investor's Business DailyHow The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
